Related Experiment Video
Updated: Aug 31, 2025
06:55
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
14.6K
Valuing Health Gain from Composite Response Endpoints for Multisystem Diseases
Sean P Gavan1, Ian N Bruce2, Katherine Payne1
1Manchester Centre for Health Economics, Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, England, UK.
Summary
Estimating health gain in multisystem diseases is crucial. Achieving response criteria, like Major Clinical Response, significantly increases quality-adjusted life-years (QALYs) and provides substantial monetary benefits.
Area of Science:
- Health Economics
- Clinical Research
- Multisystem Diseases
Background:
- Composite response endpoints are increasingly used to assess treatment effectiveness in multisystem diseases.
- Quantifying the associated health gain is essential for health technology assessment and economic evaluations.
Purpose of the Study:
- To demonstrate a method for estimating the health gain experienced by patients with multisystem diseases upon achieving a condition-specific composite response endpoint.
- To evaluate the health utility values, quality-adjusted life-years (QALYs), and monetary benefits associated with achieving response criteria.
Main Methods:
- Utilized data from systemic lupus erythematosus patients in routine practice.
- Developed and applied two bespoke composite response endpoints: Major Clinical Response and Improvement.
- Employed difference-in-differences regression to compare health utility values (EQ-5D) between responders and non-responders over 6 months.
- Used bootstrapped regression to estimate incremental QALYs, probability of QALY gain, and population monetary benefit.
Main Results:
- At 6 months, 18.2% achieved Major Clinical Response and 49.1% achieved Improvement.
- Incremental health utility values were 0.0923 for Major Clinical Response and 0.0454 for Improvement.
- Expected incremental QALY gain was 0.020 for Major Clinical Response and 0.012 for Improvement, with probabilities of QALY gain at 77.6% and 72.7%, respectively.
- Population monetary benefits were substantial: £1,106,458 for Major Clinical Response and £649,134 for Improvement.
Conclusions:
- Composite response endpoints can be effectively linked to measurable health utility gains.
- This methodology enhances the utility of composite endpoints for health technology assessment, decision-making, and economic evaluations.
- Quantifying health gain associated with response criteria is vital for understanding the true value of treatments for multisystem diseases.
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
163
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
163
01:21Rheumatic Heart Disease III: Medical Management
29
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
29
01:22Dose-Response Relationship: Potency and Efficacy
4.8K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.8K
01:25Strategies for Assessing and Addressing Confounding
146
Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
146
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:03Dose-Response Relationship: Overview
3.4K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
3.4K